ARMP240517P2500
- 0.11
- 0.000.00%
Armata Pharmaceuticals Newsroom
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic Advances
Armata Pharmaceuticals Q1 EPS $(0.69) Misses $(0.31) Estimate, Sales $966.00K Miss $1.10M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.31) by 122.58 percent. This is a 72.5 percent decrease over losses
Armata Pharmaceuticals | 10-Q: Quarterly report
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
04:14 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
Armata Pharmaceuticals 1Q Loss/Shr 69c >ARMP
Armata Pharmaceuticals 1Q Loss/Shr 69c >ARMP
Press Release: Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES, May 7, 2024 LOS ANGELES, May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc.
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Armata Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 101.15% HC Wainwright & Co. $7 → $7 Maintains Buy 08/14/2023 101.15% HC Wainwright & Co. $7 → $
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
04:09 PM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
Armata Pharmaceuticals Q4 EPS $(0.55) Misses $(0.35) Estimate, Sales $1.53M Beat $860.00K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 89.66 percent decrease over losses
Press Release: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES, March 21, 2024 LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata P
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP